Successfully encapsulates anti-cancer agent in newly invented liposome
High tumor shrinking effects and synergistic effect with an immune checkpoint inhibitor were observed
November 13, 2018
FUJIFILM Corporation (President: Kenji Sukeno) has succeeded in stably encapsulating the anti-cancer agent topotecan*1, approved for the treatment of several solid cancers, in newly invented liposome. When preclinical studies in mice were conducted using a drug where topotecan was encapsulated in liposomes (development number: FF-10850), in addition to confirming high tumor shrinking effects, improved pharmacological efficacy was demonstrated when administered in combination with an immune checkpoint inhibitor*2 , with prolonged survival compared to monotherapy. Going forward, based on the results of these nonclinical studies, the company will prepare for the early initiation of clinical studies of the drug candidate.
https://www.fujifilmusa.com/press/news/display_news?newsID=881550